Table 2a:
RBD IgG antibody levels after two and three vaccinations in patients with CKD stages G4/5 and dialysis patients categorized by use of immunosuppressive drugs.
| 2 vaccinations | 3 vaccinations | |||||||
|---|---|---|---|---|---|---|---|---|
| Immunosuppressive treatment | Immunosuppressive treatment | |||||||
| All | No | Yes | P a | All | No | Yes | P a | |
| CKD G4/5, n (%) | 400 (100) | 378 (94) | 22 (6) | 40 (100) | 31 (78) | 9 (22) | ||
| RBD IgG Ab level (BAU/mL) | 2097 (828–4077) | 2186 (887–4160) | 1110 (34–2456) | .003 | 1551 (459–3225) | 1680 (631–3466) | 11 (3–739) | .01 |
| RBD IgG seroconversion rate, n (%) | 384 (96) | 368 (97) | 16 (73) | <.001 | 32 (80) | 29 (94) | 3 (33) | <.001 |
| RBD IgG antibody level >1000 BAU/mL, n (%) | 286 (72) | 275 (73) | 11 (50) | .02 | 22 (55) | 20 (65) | 2 (22) | .03 |
| Dialysis patients, n (%) | 480 (100) | 396 (83) | 84 (18) | 242 (100) | 204 (84) | 38 (16) | ||
| RBD IgG Ab level (BAU/mL) | 1375 (431–2896) | 1798 (667–3073) | 291 (29–748) | <.001 | 1727 (570–4254) | 2309 (867–4741) | 200 (9–1102) | <.001 |
| RBD IgG seroconversion rate, n (%) | 443 (92) | 386 (97) | 57 (68) | <.001 | 222 (92) | 199 (98) | 23 (61) | <.001 |
| RBD IgG antibody level >1000 BAU/mL, n (%) | 274 (57) | 260 (66) | 14 (17) | <.001 | 153 (63) | 143 (70) | 10 (26) | <.001 |
Note: Antibody levels, seroconversion rates, and rates of high-level antibody response (>1000 BAU/ml) after two and three SARS-CoV-2 vaccinations for all CKD G4/5 and dialysis patients, and according to the use of immunosuppressive drugs.
Ab: antibody.
aNot using immunosuppressive drugs versus using immunosuppressive drugs.